Praxis Precision Medicines (NASDAQ:PRAX) Announces Earnings Results

Praxis Precision Medicines (NASDAQ:PRAX) announced its earnings results on Thursday. The company reported ($2.87) earnings per share for the quarter, topping the consensus estimate of ($3.67) by $0.80, FiscalAI reports.

Here are the key takeaways from Praxis Precision Medicines’ conference call:

• Ulixacaltamide and relutrigine remain on track for potential FDA decisions, with target dates around January 2027 and December 27, 2026, respectively. Praxis said neither program is expected to require an advisory committee meeting, and FDA mid-cycle reviews identified no significant efficacy issues.
• Praxis has substantially advanced its commercial preparations, including hiring and training the relutrigine field team, building the ulixacaltamide sales force, establishing distribution and supply networks, and developing patient-support programs. Management expects to be launch-ready ahead of the anticipated approvals.
• Enrollment in the EMERALD broad developmental and epileptic encephalopathy study exceeded its target at approximately 200 patients across more than 50 genetic etiologies. If positive, the company expects the data could support a supplemental filing for relutrigine in 2027.
• Vormatrigine’s POWER1 study failed its primary endpoint in highly refractory focal-onset seizures, although it met a key responder secondary endpoint. Praxis plans to amend POWER2 and POWER3 based on learnings about dose, treatment duration, and patient selection, with both studies expected to restart by the fourth quarter.
• Second-quarter operating expenses increased to $96.9 million and operating cash usage rose to $78 million, reflecting greater development and commercial spending. Praxis ended the quarter with $1.4 billion in cash and marketable securities, which management believes funds operations into 2028.

Praxis Precision Medicines Stock Performance

Shares of PRAX stock opened at $360.76 on Friday. The stock has a market capitalization of $10.06 billion, a P/E ratio of -27.90 and a beta of 2.78. The company has a 50 day moving average price of $303.99 and a 200 day moving average price of $315.79. Praxis Precision Medicines has a fifty-two week low of $37.19 and a fifty-two week high of $382.54.

More Praxis Precision Medicines News

Here are the key news stories impacting Praxis Precision Medicines this week:

• Positive Sentiment: Praxis said it expects two FDA decisions within roughly six months and is targeting approximately $10 billion in peak sales for ulixacaltamide. The company is also preparing a commercial organization of about 300 field employees, signaling confidence in the drug’s market potential. Praxis signals two FDA decisions and targets $10 billion in peak sales
• Positive Sentiment: Management’s planned commercial launch could exceed expectations if regulatory approvals are secured and adoption develops as projected, strengthening the long-term growth narrative for PRAX. Praxis commercial launch could smash expectations
• Positive Sentiment: Praxis reported a second-quarter loss of $2.87 per share, narrower than the $3.67 analyst consensus, providing a better-than-expected earnings result. Needham & Company also raised its price target from $575 to $582 and maintained a Buy rating. Needham raises Praxis price target Praxis corporate update and second-quarter results
• Neutral Sentiment: The company remains unprofitable and expects a full-year loss, while building a sizeable commercial infrastructure ahead of potential approvals. Those investments could increase expenses before product revenue begins.
• Negative Sentiment: With PRAX near its 52-week high, a market capitalization above $10 billion, and a high beta, the stock is vulnerable to valuation-driven profit-taking. Investors may also be locking in gains while awaiting the FDA decisions and clearer evidence of launch execution.

Insider Transactions at Praxis Precision Medicines

In other Praxis Precision Medicines news, Director Jill Desimone sold 11,600 shares of the stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $311.32, for a total transaction of $3,611,312.00. Following the sale, the director directly owned 2,337 shares in the company, valued at $727,554.84. This represents a 83.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.00% of the stock is currently owned by company insiders.

Institutional Trading of Praxis Precision Medicines

Several hedge funds have recently modified their holdings of the stock. Los Angeles Capital Management LLC acquired a new position in Praxis Precision Medicines during the 4th quarter worth $163,000. Commonwealth Equity Services LLC acquired a new stake in Praxis Precision Medicines in the 4th quarter valued at about $220,000. O Shaughnessy Asset Management LLC acquired a new stake in Praxis Precision Medicines in the 4th quarter valued at about $226,000. Amundi purchased a new position in shares of Praxis Precision Medicines in the 4th quarter valued at about $233,000. Finally, Ieq Capital LLC purchased a new position in shares of Praxis Precision Medicines in the 4th quarter valued at about $240,000. 67.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Needham & Company LLC upped their price objective on shares of Praxis Precision Medicines from $575.00 to $582.00 and gave the stock a “buy” rating in a report on Thursday. Robert W. Baird set a $514.00 target price on shares of Praxis Precision Medicines in a report on Friday. Wells Fargo & Company reissued a “positive” rating and issued a $362.00 target price (up from $323.00) on shares of Praxis Precision Medicines in a research report on Friday. Wedbush decreased their price target on Praxis Precision Medicines from $166.00 to $162.00 and set an “underperform” rating on the stock in a research note on Tuesday, June 2nd. Finally, Wall Street Zen upgraded Praxis Precision Medicines from a “sell” rating to a “hold” rating in a research note on Saturday. Four research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $573.05.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.